W World Corp. is a biopharmaceutical firm dedicated to identifying and... W World Corp. is a biopharmaceutical firm dedicated to identifying and advancing innovative treatments for various metabolic and neurological conditions. Its research and development efforts specifically target ailments related to the brain-gut axis, pain and inflammation, autoimmune diseases, and gout. The company's pipeline features two primary experimental drugs: Levotofisopam, currently in clinical trials as a non-sedative therapy for Gout, and Dextofisopam, a non-serotonergic compound that has successfully concluded Phase IIa and Phase IIb clinical trials for irritable bowel syndrome (IBS). Established in 1990, W World Corp. maintains its corporate headquarters in North Las Vegas, Nevada.
